Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. GTBP.NASDAQ

GT Biopharma Inc (GTBP NASDAQ) stock market data APIs

$2.76 -0.01(-0.4%) as of July 26, 2024
Price chart is built with Anychart

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GT Biopharma Inc Financial Data Overview

2.765
2.76
-
2.795
2.72
2.6-10.6599
5 963 K
2 157 K
0
-1.64
0.657
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GTBP',
Type: 'Common Stock',
Name: 'GT Biopharma Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000DHJ738',
ISIN: NULL,
CUSIP: NULL,
CIK: '109657',
EmployerIdNumber: '94-1620407',
FiscalYearEnd: 'December',
IPODate: '2017-09-22',
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

GT Biopharma Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -6 760 000
  • Earnings Per Share -7.01
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get GT Biopharma Inc Earnings via APIs

  • Latest Release 2024-05-15
  • EPS/Forecast -2.7

Get GT Biopharma Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get GT Biopharma Inc latest news via APIs

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company...
  • (SITC) 2023 ANNUAL MEETING
  • GT BIOPHARMA
  • GTB-5550
  • INC
  • NASDAQ:GTBP
  • POSITIVE PRECLINICAL DATA
  • PRESS RELEASES
  • PROSTATE CANCER TREATMENT
  • TRIKE® MOLECULE

GT Biopharma Reports Third Quarter 2023 Financial Results

IND submission for GTB-3650, 2nd generation nanobody TriKE® for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia a...
  • 2ND GENERATION
  • CD33+ LEUKEMIA
  • FINANCIAL RESULTS
  • GT BIOPHARMA
  • GTB-3650
  • INC
  • NANOBODY TRIKE®
  • NASDAQ:GTBP
  • PRESS RELEASES
  • THIRD QUARTER 2023
  • TREATMENT
Do you have any questions?
support@eodhistoricaldata.com